<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:     Development of Agents to Promote Cellular Ga-67 (Gallium-67) Uptake</AwardTitle>
<AwardEffectiveDate>07/01/2003</AwardEffectiveDate>
<AwardExpirationDate>03/31/2004</AwardExpirationDate>
<AwardTotalIntnAmount>99999.00</AwardTotalIntnAmount>
<AwardAmount>99999</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Om P. Sahai</SignBlockName>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research (SBIR) Phase I project is proposes to develop new pharmaceutical agents to selectively enhance tumor imaging using gallium (Ga-67).  Ga-67 has been widely used in tumor imaging and clinical medicine due to significant advantages in terms of low cost, ease of use and long life. However, the use of Ga -67 is currently limited, mainly due to varying tumor avidity and high dose requirements needed to achieve high signal-to-background ratios in non-gallium avid tumors. Increasing the selective uptake of gallium by tumor cells will dramatically improve gallium imaging, resulting in the development of an innovative, sensitive, and low-cost tumor detection tool. This Phase I program will focus on designing, preparing and evaluating novel nitrosipine derivatives with the potential to drastically increase the uptake of Ga-67 by tumor cells. &lt;br/&gt;&lt;br/&gt;The commercial application of this project is in the area of tumor imaging and oncology.&lt;br/&gt;</AbstractNarration>
<MinAmdLetterDate>06/20/2003</MinAmdLetterDate>
<MaxAmdLetterDate>01/08/2004</MaxAmdLetterDate>
<ARRAAmount/>
<AwardID>0320485</AwardID>
<Investigator>
<FirstName>Takuji</FirstName>
<LastName>Tsukamoto</LastName>
<EmailAddress>taku@chemica.com</EmailAddress>
<StartDate>06/20/2003</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Chemica Technologies Inc</Name>
<CityName>Portland</CityName>
<ZipCode>972014957</ZipCode>
<PhoneNumber>5033520262</PhoneNumber>
<StreetAddress>2611 SW Third Ave STE 250F</StreetAddress>
<CountryName>United States</CountryName>
<StateName>Oregon</StateName>
<StateCode>OR</StateCode>
</Institution>
<FoaInformation>
<Code>0203000</Code>
<Name>Health</Name>
</FoaInformation>
<FoaInformation>
<Code>0510402</Code>
<Name>Biomaterials-Short &amp; Long Terms</Name>
</FoaInformation>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>9181</Code>
<Text>BIOPROCESSING/BIOMOLECULAR MATERIALS</Text>
</ProgramReference>
<ProgramReference>
<Code>BIOT</Code>
<Text>BIOTECHNOLOGY</Text>
</ProgramReference>
</Award>
</rootTag>
